88 related articles for article (PubMed ID: 24720366)
1. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Lim SJ; Oh JK; Huang TW; Zeng YH; Wu MT; Yang HL; Cheung JP; Kim JW; Han JH; Huo L; Lin TJ; Zhou G; Wu WS
Clin Interv Aging; 2020; 15():111-121. PubMed ID: 32099341
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
[TBL] [Abstract][Full Text] [Related]
5. Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.
Jeon S; Yu D; Kim S; Kim SW; Jeon I
Osteoporos Int; 2024 May; 35(5):795-804. PubMed ID: 38261013
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis.
Sheng OC; Wu WT; Peng CH; Yao TK; Chen IH; Wang JH; Yeh KT
BMC Musculoskelet Disord; 2024 Apr; 25(1):288. PubMed ID: 38614984
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Wharton's jelly-derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study.
Shim J; Kim KT; Kim KG; Choi UY; Kyung JW; Sohn S; Lim SH; Choi H; Ahn TK; Choi HJ; Shin DE; Han I
Stem Cells Transl Med; 2021 Apr; 10(4):554-567. PubMed ID: 33326694
[TBL] [Abstract][Full Text] [Related]
8. Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study.
Yang T; Feng C; Qu Y; Wang Q; Yang Y; Wang B; Sun Z; Bao S
J Int Med Res; 2020 Feb; 48(2):300060519876744. PubMed ID: 31601158
[TBL] [Abstract][Full Text] [Related]
9. Characterization and effectiveness of a Fracture Liaison Services program in Colombia.
Valladales-Restrepo LF; Castro-Osorio EE; Ramírez-Osorio J; Echeverry-Martinez LF; Sánchez-Ríos V; Gaviria-Mendoza A; Machado-Duque ME; Machado-Alba JE
Arch Osteoporos; 2023 Oct; 18(1):124. PubMed ID: 37789128
[TBL] [Abstract][Full Text] [Related]
10. Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.
Hald JD; Keerie C; Weir CJ; Javaid MK; Lam W; Osborne P; Walsh J; Langdahl BL; Ralston SH
BMJ Open; 2023 Nov; 13(11):e078164. PubMed ID: 37993151
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy- and lactation-associated osteoporosis with vertebral fractures: a systematic review.
Qian Y; Wang L; Yu L; Huang W
BMC Musculoskelet Disord; 2021 Nov; 22(1):926. PubMed ID: 34732196
[TBL] [Abstract][Full Text] [Related]
12. [Chinese expert consensus on treatment of osteoporotic fractures with teriparatide (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1456-1465. PubMed ID: 38706051
[TBL] [Abstract][Full Text] [Related]
13. Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study.
Martínez-Laguna D; Carbonell Abella C; Bastida JC; González M; Micó-Pérez RM; Vargas F; Díaz Torres E; Canals L;
Arch Osteoporos; 2024 May; 19(1):35. PubMed ID: 38722400
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study of osteoporosis management after a fragility fracture in primary care.
Bell A; Kendler DL; Khan AA; Shapiro C M M; Morisset A; Leung JP; Reiner M; Colgan SM; Slatkovska L; Packalen M
Arch Osteoporos; 2022 May; 17(1):75. PubMed ID: 35513573
[TBL] [Abstract][Full Text] [Related]
15. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database.
Hagino H; Yoshinaga Y; Hamaya E; Lin TC; Ajmera M; Meyers J
Arch Osteoporos; 2023 Jan; 18(1):23. PubMed ID: 36683098
[TBL] [Abstract][Full Text] [Related]
16. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up.
Kyvernitakis I; Reuter TC; Hellmeyer L; Hars O; Hadji P
Osteoporos Int; 2018 Jan; 29(1):135-142. PubMed ID: 28965212
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide for osteoporosis: importance of the full course.
Lindsay R; Krege JH; Marin F; Jin L; Stepan JJ
Osteoporos Int; 2016 Aug; 27(8):2395-410. PubMed ID: 26902094
[TBL] [Abstract][Full Text] [Related]
18. Is Teriparatide Superior in Treating Osteoporotic Vertebral Compression Fractures in Comparison to Bisphosphonates Treatment Alone: A 2-Year Retrospective Analysis.
Nair VV; Kundnani V; Shetty A; Anand M; Jain M; Dewnany N
Asian Spine J; 2023 Dec; 17(6):1098-1107. PubMed ID: 38050359
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades.
Orhadje E; Berg K; Hauser B; Ralston SH
Calcif Tissue Int; 2023 Dec; 113(6):591-596. PubMed ID: 37819437
[TBL] [Abstract][Full Text] [Related]
20. The Nottingham Spinal Health (NoSH) Study: a cohort study of patients hospitalised with vertebral fragility fractures.
Ong T; Sahota O; Gladman JRF
Osteoporos Int; 2020 Feb; 31(2):363-370. PubMed ID: 31696271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
